Director at Enveric Biosciences (ENVB) receives 18,518 restricted shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

WEBB MICHAEL D reported acquisition or exercise transactions in this Form 4 filing.

Enveric Biosciences director Michael D. Webb received a grant of 18,518 shares of restricted common stock. The award was made under the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan as amended, with vesting governed by the plan and his restricted stock agreement.

These shares were granted at no cash cost per share and are compensation rather than an open-market purchase. Following this grant, Webb directly holds a total of 26,416 shares of Enveric Biosciences common stock, subject to the vesting terms of the award.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider WEBB MICHAEL D

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	18,518	$0.00	--

Holdings After Transaction: Common Stock — 26,416 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Restricted shares granted: 18,518 shares Total shares after grant: 26,416 shares Grant price per share: $0.0000 per share +1 more

4 metrics

Restricted shares granted 18,518 shares Grant to director Michael D. Webb on June 1, 2026

Total shares after grant 26,416 shares Direct holdings of Michael D. Webb following transaction

Grant price per share $0.0000 per share Compensation grant under 2020 Long-Term Incentive Plan

Transaction code A (Grant, award, or other acquisition) Indicates restricted stock award, not market purchase or sale

Key Terms

restricted stock, 2020 Long-Term Incentive Plan, vesting

3 terms

restricted stock financial

"Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

2020 Long-Term Incentive Plan financial

"pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended"

vesting financial

"Such shares shall vest in accordance with the terms and conditions of the Plan"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/03/2026 - 04:29 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WEBB MICHAEL D

(Last)

(First)

(Middle)

245 FIRST STREET, RIVERVIEW II

18TH FLOOR

(Street)

CAMBRIDGE

MASSACHUSETTS

02142

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Enveric Biosciences, Inc. [ ENVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/01/2026		A		18,518⁽¹⁾	A	$0	26,416	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the "Plan"). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement.

	/s/ Michael D. Webb	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Enveric Biosciences (ENVB) report for Michael D. Webb?

Enveric Biosciences reported that director Michael D. Webb received 18,518 shares of restricted common stock as a compensation grant. The award was issued at no cash cost under the company’s 2020 Long-Term Incentive Plan and is subject to vesting conditions set by that plan.

How many Enveric Biosciences (ENVB) shares does Michael D. Webb hold after this Form 4 grant?

After the reported grant, Michael D. Webb directly holds 26,416 shares of Enveric Biosciences common stock. This total includes the newly granted 18,518 restricted shares, which will vest over time according to the company’s 2020 Long-Term Incentive Plan and his award agreement.

Was the Enveric Biosciences (ENVB) Form 4 transaction an open-market purchase or a stock grant?

The Form 4 reflects a stock grant, not an open-market purchase. Director Michael D. Webb received 18,518 restricted shares at a stated price of $0.0000 per share as compensation under Enveric’s 2020 Long-Term Incentive Plan, subject to standard vesting terms and conditions.

Under which plan was Michael D. Webb’s Enveric Biosciences (ENVB) stock grant made?

The restricted stock grant to Michael D. Webb was made under the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended. The plan and his restricted stock award agreement govern how and when the 18,518 granted shares will vest and become fully owned.

What does it mean that Michael D. Webb’s Enveric Biosciences (ENVB) shares are restricted stock?

Restricted stock means the 18,518 granted shares are subject to vesting and other conditions before becoming fully transferable. For Michael D. Webb, the vesting schedule and requirements are defined in Enveric’s 2020 Long-Term Incentive Plan and his individual restricted stock award agreement.